Immune cells and growth-factor signals in aggressive breast cancer disparities

Immune Microenvironments and Hepatocyte Growth Factor Signaling Interactions in Breast Cancer Disparities

NIH-funded research North Carolina Central University · NIH-11111286

Looking at how immune cells and a growth signal called HGF interact in aggressive breast cancers that affect some communities more, to better understand why outcomes differ.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionNorth Carolina Central University NIH-funded
Lab location1 site (Durham, United States)
Project IDNIH-11111286 on NIH RePORTER

What this research studies

Researchers will compare immune and stromal cells and protein signals in tumor and normal breast tissue from people with aggressive breast cancers, especially basal-like and inflammatory types. They will examine differences between population groups that experience higher death rates to find patterns linked to worse outcomes. Lab models and human tissue samples will be used to trace how stromal cells and HGF signaling may help tumors grow and spread. The goal is to reveal population-specific mechanisms that could point to better ways to detect or treat these lethal breast cancers.

Who could benefit from this research

Good fit: Ideal candidates would be people diagnosed with basal-like (hormone receptor–negative) or inflammatory breast cancer, especially from populations with higher mortality who can provide tissue samples or clinical data.

Not a fit: People with non-aggressive, hormone receptor–positive breast cancers or unrelated health conditions are unlikely to benefit directly from this project.

Why it matters

Potential benefit: If successful, this work could identify biological reasons for worse outcomes in some groups and point to new targets or strategies to improve detection and treatment of aggressive breast cancers.

How similar studies have performed: Prior research has shown the tumor immune environment matters for outcomes, but studying HGF-driven stromal interactions in the context of population disparities is relatively new.

Where this research is happening

Durham, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Breast CancerBreast Cancer PatientCancerous
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.